Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MELK | Q14680 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012640 | 0.85 | EGFR (0.38) | HPGDSPDGFRBPDGFRAALDH1A1MELK | |
| SCHEMBL5118002 | 0.81 | HPGDS (0.53) | HPGDSPDGFRBPDGFRAMAP4K4HTT | |
| SCHEMBL28292066 | 0.80 | HPGDS (0.51) | HPGDSPDGFRBPDGFRAMAP4K4HTT | |
| SCHEMBL232457 | 0.77 | ALDH1A1 (0.57) | PDGFRBPDGFRAALDH1A1CYP2A6RAB9A | |
| SCHEMBL276229 | 0.75 | PDGFRB (0.39) | HPGDSPDGFRBPDGFRAALDH1A1MAPK10 | |
| SCHEMBL2010292 | 0.73 | MELK (0.49) | MELK | |
| SCHEMBL2006717 | 0.73 | MELK (0.57) | MELKCSNK1DCSNK1ECLK1DYRK1A | |
| SCHEMBL25216279 | 0.71 | PDGFRB (0.47) | HPGDSPDGFRBPDGFRAALDH1A1MAPK10 | |
| SCHEMBL18583892 | 0.71 | MAPT (0.40) | HPGDSPDGFRBPDGFRAALDH1A1MAPK10 | |
| SCHEMBL22384535 | 0.71 | PDGFRB (0.39) | HPGDSPDGFRBPDGFRAALDH1A1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | HPGDS 3876/4885PDGFRB 2080/4885PDGFRA 1733/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | HPGDS 2420/4885PDGFRB 2422/4885PDGFRA 1916/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | HPGDS 4205/4885PDGFRB 3357/4885PDGFRA 2650/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | HPGDS 3844/4885PDGFRB 2529/4885PDGFRA 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.